drugset / Trial / NCT03066219

Safety and Efficacy of BRM421 for Dry Eye Syndrome

NCT03066219 ↗

Phase 2 Completed 157 enrolled BRIM Biotechnology Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Timeline

Start
2017-02-07
Primary completion
2017-05-20
Completion
2017-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator BRM421 Unknown 0.03 % Other

Indications